CEREVEL SHAREHOLDER REMINDER: Is $45 Per Share Enough for Cerevel (Nasdaq: CERE)? BFA Law is Investigating and Encourages Investors to Contact the Firm
Cerevel Therapeutics Holdings, Inc. (CERE)
Company Research
Source: GlobeNewswire
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE) and AbbVie, Inc. If you invested in Cerevel Therapeutics you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/cerevel-therapeutics-holdings-inc-investigation. Claim Details: On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie. Under the terms of the transaction, AbbVie will acquire all outstanding shares of Cerevel for $45.00 per share in cash. The transaction values Cerevel at a total equity value of approximately $8.7 billion. The boards of directors of both companies have approved the transaction. This transaction is expected to close in the middle of 2024. BFA is currently investigating the go private transaction and believes that Cerevel Therapeutics’ board of directors was conflicted, engaged in an unfair process, and a
Show less
Read more
Impact Snapshot
Event Time:
CERE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CERE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CERE alerts
High impacting Cerevel Therapeutics Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
CERE
News
- CEREVEL (NASDAQ:CERE) INVESTOR UPDATE: Cerevel’s $45 Per Share Offer is Being Investigated by BFA Law, Shareholders are Urged to Contact the FirmAccesswire
- An Investigation Into Cerevel Therapeutics Holdings Inc Is Being Undertaken By The Schall Law Firm And Shareholders Of CERE Can JoinAccesswire
- The Schall Law Firm Is Leading An Investigation Into Cerevel Therapeutics Holdings Inc And CERE Shareholders Are Invited To Be InvolvedAccesswire
- CEREVEL (NASDAQ:CERE) INVESTOR ALERT: Cerevel’s $45 Per Share Offer is Being Investigated by BFA Law, Shareholders are Encouraged to Contact the FirmGlobeNewswire
- CEREVEL INVESTOR NOTICE: Cerevel’s (NYSE:CERE) $45 Per Share Offer is Being Investigated by BFA Law, Shareholders are Reminded to Contact the Firm Accesswire
CERE
Earnings
- 5/8/24 - Miss
CERE
Sec Filings
- 6/7/24 - Form 4
- 6/7/24 - Form 4
- 6/7/24 - Form 4
- CERE's page on the SEC website